European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C MutationPRNewsWire • 01/10/24
Mirati (MRTX) Up 1.1% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/06/23
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination ProcedurePRNewsWire • 11/10/23
MIRATI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTXBusiness Wire • 11/08/23
Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesPRNewsWire • 11/06/23
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C MutationPRNewsWire • 11/03/23
Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)PRNewsWire • 10/17/23
MIRATI THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTXBusiness Wire • 10/09/23
Bristol Myers Squibb to buy cancer drugmaker Mirati Therapeutics in up to $5.8B dealFox Business • 10/09/23
Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball BidInvestors Business Daily • 10/09/23
Shareholder Alert: Ademi LLP investigates whether Mirati Therapeutics, Inc. has obtained a Fair Price in its transaction with Bristol Myers SquibbPRNewsWire • 10/09/23
Mirati Stock Falls as Bristol Myers to Buy Oncology Developer for Up to $5.8 BillionBarrons • 10/09/23
Bristol-Myers Squibb enahnces oncology portfolio in deal worth up to $5.8bnProactive Investors • 10/09/23
MRTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Mirati Therapeutics, Inc. Is Fair to ShareholdersBusiness Wire • 10/09/23
Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billionMarket Watch • 10/08/23